Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir

The CC polymorphism at IL-28B rs12979860 is associated with response to triple therapy and can identify candidates for shorter treatment durations. A ≥1 log10 decrease in HCV RNA at week 4 of therapy is the strongest predictor of a SVR, regardless of polymorphisms in IL-28B. ClinicalTrials.gov; numbers NCT00705432 and NCT00708500.